Podcast: Key takeaways from EASD 2026 on where GLP-1s are headed - Pharmaceutical Technology

Experts discuss the latest research released at EASD 2026 and what it could mean for the diabetes community. Experts discuss the latest research released at EASD 2026 and what it could mean for the diabetes community. The latest trends emerging from the European Association for the Study of Diabetes (EASD) 2026 meeting forecast a competitive space for diabetes treatments in the years to come. Image credit: GlobalData/Shutterstock [Gecko Studio] The world of diabetes and obesity research has exploded in recent years with the blockbuster success of glucagon-like peptide (GLP)-1 therapies and the rapid pace of innovation seen with next-generation therapies.…

Source: Pharmaceutical Technology